Resultados da pesquisa - C. Mulargiu

  • A mostrar 1 - 2 resultados de 2
Refinar resultados
  1. 1
    The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies

    The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open fo... Por Alessandra Ferro, G.M. Marinato, C. Mulargiu, Mónica Marino, Giulia Pasello, Valentina Guarneri, Laura Bonanno

    Publicado em 2024
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  2. 2
    Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

    Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671) Por Claudia Proto, M. Ganzinelli, Sara Manglaviti, Martina Imbimbo, Giulia Galli, Mirko Marabese, Fabiana Zollo, M.F. Alvisi, M. Perrino, Nadia Cordua, Federica Borea, Fabio De Vincenzo, A. Chella, Susanna Cappelli, E. Pardini, Z. Ballatore, A. Lucarelli, Elisa Ambrosini, Mariateresa Giuliano, Erica Pietroluongo, C. Mulargiu, Agnese Fabbri, Arsela Prelaj, Mario Occhipinti, M. Brambilla, L. Mazzeo, T. Beninato, R. Vigorito, Margherita Ruggirello, Francesca Gabriella Greco, G. Calareso, Daniela Miliziano, Eliana Rulli, Irene De Simone, Valter Torri, Filippo de Braud, G. Pasello, Pietro De Placido, Romeo S. Berardi, Iacopo Petrini, Paolo Andrea Zucali, Marina Chiara Garassino, G. Lo Russo

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: